- Home
- XYL vs RPRX Comparison
XYL vs RPRX Comparison
Compare XYL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XYL | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.0B | 25.9B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XYL | RPRX |
|---|---|---|
| Price | $104.06 | $56.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $153.88 | $65.13 |
| AVG Volume (30 Days) | 2.3M | ★ 2.8M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.68% | 1.66% |
| EPS Growth | ★ 7.40 | N/A |
| EPS | ★ 1.90 | 0.71 |
| Revenue | ★ $9,035,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $1.89 | $47.32 |
| Revenue Next Year | $4.61 | $8.70 |
| P/E Ratio | ★ $53.99 | $79.82 |
| Revenue Growth | ★ 5.52 | 5.06 |
| 52 Week Low | $98.58 | $35.23 |
| 52 Week High | $154.27 | $64.38 |
Technical Indicators
Market Signals| Indicator | XYL | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 33.26 |
| Support Level | N/A | $56.36 |
| Resistance Level | $125.73 | $56.50 |
| Average True Range (ATR) | 2.43 | 1.05 |
| MACD | 0.06 | -0.23 |
| Stochastic Oscillator | 48.93 | 13.86 |
Price Performance
Historical ComparisonAbout XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.